<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860505</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002242</org_study_id>
    <secondary_id>0000058968</secondary_id>
    <nct_id>NCT04860505</nct_id>
  </id_info>
  <brief_title>Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens</brief_title>
  <official_title>Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine tissue pharmacology of a single dose of doxycycline for sexually&#xD;
      transmitted infection (STI) Post-exposure Prophylaxis (PEP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine tissue pharmacology of a single dose of doxycycline for STI PEP, investigators&#xD;
      at Emory University will collaborate with the Centers for Disease Control and Prevention&#xD;
      (CDC) to conduct a clinical trial of up to 20 men who have sex with men (MSM) and women aged&#xD;
      18-59, with measurement of anti-retroviral drug and doxycycline concentrations in the rectum&#xD;
      and vaginal regions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rectal doxycycline concentration</measure>
    <time_frame>24 hours after a single dose</time_frame>
    <description>Rectal doxycycline concentration will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal doxycycline concentration</measure>
    <time_frame>24 hours after a single dose</time_frame>
    <description>Vaginal doxycycline concentration will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma doxycycline concentration</measure>
    <time_frame>24 hours after a single dose</time_frame>
    <description>Plasma doxycycline concentration will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rectal Biktarvy concentration</measure>
    <time_frame>24 hours after a single dose</time_frame>
    <description>Rectal anti-retroviral drug concentration will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Biktarvy concentration</measure>
    <time_frame>24 hours after a single dose</time_frame>
    <description>Vaginal anti-retroviral drug concentration will be measured</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sexually Transmitted Diseases</condition>
  <arm_group>
    <arm_group_label>Doxycycline and Biktarvy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline (DOX [200 mg]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.</description>
    <arm_group_label>Doxycycline and Biktarvy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy</intervention_name>
    <description>Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.</description>
    <arm_group_label>Doxycycline and Biktarvy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV negative person, who was assigned male or female at birth, who reports sex with&#xD;
             another man in the last year and is in good general health&#xD;
&#xD;
          2. Aged 18-59 years&#xD;
&#xD;
          3. Not currently taking PrEP and no plans to initiate during study&#xD;
&#xD;
          4. Not currently taking PEP&#xD;
&#xD;
          5. Not currently taking doxycycline or other tetracycline-derived antibiotics and no&#xD;
             plans to initiate during the study&#xD;
&#xD;
          6. Willing to use condoms consistently for the duration of the study&#xD;
&#xD;
          7. Able to provide informed consent in English&#xD;
&#xD;
          8. No plans for relocation in the next 4 months&#xD;
&#xD;
          9. Willing to undergo peripheral blood, urine, rectal or vaginal secretion collection,&#xD;
             and a rectal or vaginal and cervical biopsy procedure&#xD;
&#xD;
         10. Willing to use study products as directed&#xD;
&#xD;
         11. Hepatitis B surface antigen (HBsAg) negative (screening lab test)&#xD;
&#xD;
         12. Creatinine clearance &gt;60 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently infected with hepatitis virus and/ or has liver disease&#xD;
&#xD;
          2. Current or chronic history of kidney disease or creatinine clearance (CrCl)&lt;60 ml/min&#xD;
&#xD;
          3. Continued need for, or use during the 90 days prior to enrollment, of the following&#xD;
             medications:&#xD;
&#xD;
               1. Systemic immunomodulatory agents&#xD;
&#xD;
               2. Supraphysiologic doses of steroids (short course steroids less than 7 days&#xD;
                  duration, allowable at the discretion of the investigators)&#xD;
&#xD;
               3. Chemotherapy or radiation for treatment of malignancy&#xD;
&#xD;
               4. Experimental medications, vaccines, or biologicals&#xD;
&#xD;
          4. Intent to use HIV antiretroviral pre/post-exposure prophylaxis (PrEP or PEP) during&#xD;
             the study, outside of the study procedures&#xD;
&#xD;
          5. Intent to use doxycycline or other tetracycline-derived antibiotics during the course&#xD;
             of the study, outside of the study procedures&#xD;
&#xD;
          6. Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             investigator, would make the patient unsuitable for the study or unable to comply with&#xD;
             the study requirements&#xD;
&#xD;
          7. Not pregnant and no plans on getting pregnant throughout the duration of the study&#xD;
&#xD;
          8. Known allergic reaction to study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Kelley, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Kelley, MD, MPH</last_name>
    <phone>404-712-1823</phone>
    <email>colleen.kelley@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hope Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kelley, MD, MPH</last_name>
      <phone>404-712-1823</phone>
      <email>colleen.kelley@emory.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Colleen Kelley</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Post-Exposure Prophylaxis</keyword>
  <keyword>HIV</keyword>
  <keyword>STI</keyword>
  <keyword>PEP</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results published for this study (including text, tables, figures, and appendices), will be made available for sharing, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be made available to researchers providing a methodologically sound proposal, beginning 9 months and ending 36 months following publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to colleen.kelley@emory.edu. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

